(Reuters) - Bristol-Myers Squibb (BMY.N) may win U.S. approval as early as this week for the first drug shown to extend survival for patients with a deadly form of skin cancer.
(Reuters) - Bristol-Myers Squibb (BMY.N) may win U.S. approval as early as this week for the first drug shown to extend survival for patients with a deadly form of skin cancer.
